קסלג'אנז 5 מג
pfizer pharmaceuticals israel ltd - tofacitinib - טבליה - tofacitinib 5 mg - tofacitinib
קסלג'אנז 5 מג
pfizer pharmaceuticals israel ltd - tofacitinib - טבליה - tofacitinib 5 mg - tofacitinib
רפמיון 1 מג טבליות
pfizer pharmaceuticals israel ltd - sirolimus - טבליות מצופות - sirolimus 1 mg - sirolimus
טלזנה 0.25 מג
pfizer pharmaceuticals israel ltd - talazoparib as tosylate - קפסולה קשיחה - talazoparib as tosylate 0.25 mg - talazoparib
טלזנה 1 מג
pfizer pharmaceuticals israel ltd - talazoparib as tosylate - קפסולה קשיחה - talazoparib as tosylate 1 mg - talazoparib
לורביקואה 25 מג
pfizer pharmaceuticals israel ltd - lorlatinib - טבליות מצופות פילם - lorlatinib 25 mg - lorlatinib
לורביקואה 100 מג
pfizer pharmaceuticals israel ltd - lorlatinib - טבליות מצופות פילם - lorlatinib 100 mg - lorlatinib
קסלג'אנז 10 מג
pfizer pharmaceuticals israel ltd - tofacitinib - טבליה - tofacitinib 10 mg - tofacitinib
זיבוקסיד 600 מג
pfizer pfe pharmaceuticals israel ltd - linezolid - טבליה - linezolid 600 mg - linezolid - linezolid - therapy is indicated only when an organism resistant to all other antibiotics is suspected. zyvoxid is indicated in adult and pediatric patients for the treatment of infections when known or suspected to be caused by susceptible organisms including those associated with concurrent bacteraemia such as: 1) pneumonia - community acquired and nosocomial pneumonia including multi drug resistant streptococcus pneumonia (mdrsp). 2) skin and soft tissue infections including diabetic foot infections. 3) enterococcal infections. combination therapy may be indicated if a concomitant gram negative pathogen is documented or suspected.
בוסולפקס
tzamal bio-pharma ltd - busulfan - תמיסה להזרקה - busulfan 60 mg / 10 ml - busulfan - busulfan - for use in combination with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to hematopoietic progenitor cell transplantation.